Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


DRI Capital Celebrates 20 Years of Healthcare Royalty Investing

TORONTO, Jan. 6, 2013 /PRNewswire/ -- DRI Capital ("DRI"), a pioneer in the global field of pharmaceutical royalty monetization, is pleased to announce the completion of over $600 million in transactions for 2012. Formerly known as Drug Royalty Corporation, DRI is celebrating its 20th anniversary in 2013. As the original firm to monetize pharmaceutical royalties, DRI and its managed funds have been instrumental in helping to create the robust and liquid market for the recipients of royalties on healthcare related products that exists today.

Over the past 20 years DRI has worked with more healthcare royalty recipients than any other royalty monetization firm, and its managed funds have completed the most royalty transactions and purchased the most royalty entitlements. DRI's Drug Royalty funds currently hold what DRI believes to be the most diversified portfolio of healthcare royalty entitlements in the industry today. In building this portfolio, DRI led the way with numerous milestone transactions, including the first transaction outside the United States, the first transaction with an individual inventor, the first transaction on a diagnostic, the first transaction on a life science tool and the first transaction involving a bundle of royalty streams. Further, DRI's managed funds have completed more repeat transactions with prior counterparties than any other, reinforcing DRI's leading reputation in the industry.

2012 marked a banner year for DRI with its Drug Royalty II and managed funds committing over $600 million while purchasing six individual royalty entitlements, each on medically necessary, market leading products. In 2012 DRI's funds continued to lead the evolution of royalty monetization by completing the first ARTS™ structured investment. This novel structure innovated by DRI enables life sciences companies to accelerate payments by selling their long-term royalty and related rights in exchange for larger payments over a shorter period.

"Over the past 20 years it has been a privilege to work with some of the world's leading academic institutions, pharmaceutical & biotechnology companies and individual inventors. We value the many relationships we have formed in the life sciences community over the years and are excited to see the proceeds of these transactions continue to advance science," said Behzad Khosrowshahi, President and CEO of DRI. "We saw our most robust year in 2012 in terms of capital allocated, and our managed funds will continue to provide capital to royalty recipients. Based on our current pipeline and what we are seeing in the market today, we believe 2013 will be another groundbreaking year."

DRI will be attending the J.P. Morgan Healthcare Conference from January 7th to 10th, 2013 and the AUTM Annual Meeting from February 27th to March 2nd, 2013. 

About DRI Capital

Based in Toronto, Canada, DRI Capital Inc. (formerly Drug Royalty Corporation Inc.) is a life sciences industry-focused investment management firm with approximately US$2 billion under management that acquires royalties from universities, inventors, research institutes and pharmaceutical and biotechnology companies. DRI Capital-managed funds have completed 20 royalty transactions over the past two and a half years. Royalties recently acquired by DRI Capital's managed funds include those on Johnson and Johnson's REMICADE®, Amgen and Pfizer's ENBREL® and Biogen Idec and Elan's TYSABRI®. Additional information about DRI Capital is available at www.dricapital.com.

DRI Capital Contact:
Jeff Pootoolal
Principal
(416) 562-8911
jp@dricapital.com

SOURCE DRI Capital

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
A few weeks back, I wrote a post about getting ready to address a coworker's bad code. This sparked some conversation across various media, including the following interesting question: ...seems that there is a breakdown in managing the development process. Why is Bob allowed [to kee...
Tune into: a cloud mindset One of the tenets of the cloud religion is that it should be possible – through the use of intelligent software – to build reliable systems on top of unreliable hardware. Just like you can build reliable and affordable storage systems using RAID (...
DevOps has traditionally played important roles in development and IT operations, but the practice is quickly becoming core to other business functions such as customer success, business intelligence, and marketing analytics. Modern marketers today are driven by data and rely on many ...
Listen closely to the background hum of any agile shop, and you'll likely hear this ongoing chant: Automate! Automate! Automate! While automation can be incredibly valuable to the agile process, there are some key things to keep in mind when it comes to automated performance testing. ...
Developers are – despite their attention to what is considered a very logic-based field of study – a very creative group. Give them a hurdle to overcome and they will. The problem, of course, is not that they’ve solved a problem, it’s that in doing so they’ve likely created a source of...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE